Registered title, quoted from ClinicalTrials.gov
EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial
An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Zhongda Hospital, Southeast University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07187284, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Diagnosis of CNLC Stage IIIa HCC with portal vein tumor thrombus (vp type 1-3) confirmed by histopathology, cytology, or imaging.
Inclusion criterion 2
ECOG performance status of 0 to 2.
Inclusion criterion 6
At least one measurable lesion according to RECIST 1.1 criteria.
Inclusion criterion 4
History of other malignancies within the past 5 years or concurrent other malignancies.
Exclusion criterion 14
Pregnant or lactating women, or individuals with childbearing potential planning pregnancy during the trial period.
Exclusion criterion 12
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07187284, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Aged 18 to 75 years (inclusive), regardless of gender.
- Diagnosis of CNLC Stage IIIa HCC with portal vein tumor thrombus (vp type 1-3) confirmed by histopathology, cytology, or imaging.
- Progression of disease after first-line systemic therapy.
- At least one measurable lesion according to RECIST 1.1 criteria.
- Child-Pugh class A or B.
- ECOG performance status of 0 to 2.
- Scheduled to undergo TACE or HAIC treatment.
- Adequate hematological, hepatic, and renal function within 14 days prior to study initiation, defined as:
White blood cell count ≥2.0×10⁹/L AND neutrophil count ≥1.0×10⁹/L. Platelet count ≥60×10⁹/L. Hemoglobin concentration ≥90 g/L. Total bilirubin ≤2.0 × upper limit of normal (ULN). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5 × ULN. Albumin ≥2.8 g/dL. International normalized ratio (INR) ≤1.6. Creatinine ≤1.5 × ULN AND calculated creatinine clearance ≥30 mL/min.
Exclusion Criteria:
- Preoperative abdominal CT or MR enhanced scan suggests celiac trunk anatomy is unsuitable for EDN procedure.
- History of orthostatic hypotension.
- Diffuse liver tumors or extensive extrahepatic metastases with an expected survival of <3 months.
- Cachexia or multi-organ failure.
- Severe hepatic dysfunction (Child-Pugh class C).
- Uncorrectable coagulation dysfunction.
- Presence of severe concurrent infection.
- Accompanied by Vp4 type portal vein tumor thrombus.
- Abnormal blood supply to the target lesion that precludes transarterial interventional therapy.
- History of bilioenteric anastomosis within the past year.
- Severe allergy to known contrast agents or embolization materials.
- Pregnant or lactating women, or individuals with childbearing potential planning pregnancy during the trial period.
- Clinically significant (e.g., active) cardiovascular disease, including:
Unstable angina within ≤6 months prior to randomization. New York Heart Association (NYHA) class ≥II congestive heart failure. Poorly controlled arrhythmia despite medication (patients with controlled atrial fibrillation are eligible), or any clinically significant abnormality found on resting ECG.
≥Grade 3 peripheral vascular disease (e.g., symptomatic and interfering with activities of daily living, requiring intervention).
Transient ischemic attack or subarachnoid hemorrhage within 6 months prior to randomization, or participation in other drug or device clinical trials within 3 months.
- History of other malignancies within the past 5 years or concurrent other malignancies.
- Any other condition deemed by the investigator as unsuitable for participation in this study.
Quoted from ClinicalTrials.gov, NCT07187284, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07187284, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.